FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065367739> ?p ?o ?g. }

• W2065367739 endingPage "S241" @default.
• W2065367739 startingPage "S241" @default.
• W2065367739 abstract "Purpose/Objective(s)To present our early clinical experience with IG-IMRT for the treatment of single or multiple brain metastases using a SIB to visible tumor while delivering a prophylactic dose to WB with a single isocenter.Materials/MethodsEight patients were treated from 7/07 through 1/08 using IG-IMRT to deliver a SIB to tumor (GTV + 3mm = PTV) with WBRT to a lower “prophylactic” dose. The median patient age was 55.5 (range, 40-71) years. Primary cancers included lung (4), melanoma, biliary, uterine, and unknown primary. The median KPS was 60 (range, 40-80). The mean number of metastases was 3.75 (range, 1-13). All patients had uncontrolled systemic disease at the time of simulation and 4 were given concurrent radiation therapy to extracranial sites. No patient received prior WBRT.The CT images were fused with pretreatment MRIs for inverse treatment planning on Pinnacle v7.4f. A standard Aquaplast mask was used for immobilization. Frameless IGRT with BrainLAB's ExacTrac with body markers for infrared tracking was used to monitor intrafraction motion. A non-coplanar, 5-field beam arrangement was delivered using a Siemen's Primus linac. Optic structures, parotids, inner ear, and scalp were optimized to minimize toxicity.ResultsAll treatments were delivered within a 30-minute treatment slot. The median total PTV was 20.3 (range, 10.1-169.3) cm3. The median prescribed dose to tumor PTV was 45 (range, 40-45) Gy, median dose to WB (excluding metastasis) was 30 (range, 25-36) Gy, delivered over a median of 15 fractions (range, 10-15). The median PTV coverages were a maximum of 105% and a minimum of 91%.Acute toxicities included 2 patients with Grade 2 (G2) fatigue and 1 patient with G2 alopecia. Common G1 toxicities were rash/dermatitis (7/8) and alopecia (8/8). There were no toxicities >G2. One patient had G2 limb weakness prior to treatment that improved to G1. Two patients had G2 aphasia prior to RT: 1 improved to G1 and another showed complete resolution.Five patients underwent posttreatment MRI at a median time of 112 (range, 45-194) days after the start of treatment. Local brain control was achieved in 16 of 17 total metastatic sites. One of 5 patients had new brain mets. Response rate was partial in 3 patients, complete in 1, and stable in another. No patients had brain necrosis.ConclusionsLow-dose “prophylactic” WBRT can be safely delivered with SIB to brain metastases with minimal toxicity and local control that is comparable to sequential WBRT and stereotactic radiosurgery (SRS). This technique is convenient, non-invasive, and may combine the benefits of WBRT and SRS into one procedure. We are currently accruing patients to further assess toxicity and tumor control using this approach. Purpose/Objective(s)To present our early clinical experience with IG-IMRT for the treatment of single or multiple brain metastases using a SIB to visible tumor while delivering a prophylactic dose to WB with a single isocenter. To present our early clinical experience with IG-IMRT for the treatment of single or multiple brain metastases using a SIB to visible tumor while delivering a prophylactic dose to WB with a single isocenter. Materials/MethodsEight patients were treated from 7/07 through 1/08 using IG-IMRT to deliver a SIB to tumor (GTV + 3mm = PTV) with WBRT to a lower “prophylactic” dose. The median patient age was 55.5 (range, 40-71) years. Primary cancers included lung (4), melanoma, biliary, uterine, and unknown primary. The median KPS was 60 (range, 40-80). The mean number of metastases was 3.75 (range, 1-13). All patients had uncontrolled systemic disease at the time of simulation and 4 were given concurrent radiation therapy to extracranial sites. No patient received prior WBRT.The CT images were fused with pretreatment MRIs for inverse treatment planning on Pinnacle v7.4f. A standard Aquaplast mask was used for immobilization. Frameless IGRT with BrainLAB's ExacTrac with body markers for infrared tracking was used to monitor intrafraction motion. A non-coplanar, 5-field beam arrangement was delivered using a Siemen's Primus linac. Optic structures, parotids, inner ear, and scalp were optimized to minimize toxicity. Eight patients were treated from 7/07 through 1/08 using IG-IMRT to deliver a SIB to tumor (GTV + 3mm = PTV) with WBRT to a lower “prophylactic” dose. The median patient age was 55.5 (range, 40-71) years. Primary cancers included lung (4), melanoma, biliary, uterine, and unknown primary. The median KPS was 60 (range, 40-80). The mean number of metastases was 3.75 (range, 1-13). All patients had uncontrolled systemic disease at the time of simulation and 4 were given concurrent radiation therapy to extracranial sites. No patient received prior WBRT. The CT images were fused with pretreatment MRIs for inverse treatment planning on Pinnacle v7.4f. A standard Aquaplast mask was used for immobilization. Frameless IGRT with BrainLAB's ExacTrac with body markers for infrared tracking was used to monitor intrafraction motion. A non-coplanar, 5-field beam arrangement was delivered using a Siemen's Primus linac. Optic structures, parotids, inner ear, and scalp were optimized to minimize toxicity. ResultsAll treatments were delivered within a 30-minute treatment slot. The median total PTV was 20.3 (range, 10.1-169.3) cm3. The median prescribed dose to tumor PTV was 45 (range, 40-45) Gy, median dose to WB (excluding metastasis) was 30 (range, 25-36) Gy, delivered over a median of 15 fractions (range, 10-15). The median PTV coverages were a maximum of 105% and a minimum of 91%.Acute toxicities included 2 patients with Grade 2 (G2) fatigue and 1 patient with G2 alopecia. Common G1 toxicities were rash/dermatitis (7/8) and alopecia (8/8). There were no toxicities >G2. One patient had G2 limb weakness prior to treatment that improved to G1. Two patients had G2 aphasia prior to RT: 1 improved to G1 and another showed complete resolution.Five patients underwent posttreatment MRI at a median time of 112 (range, 45-194) days after the start of treatment. Local brain control was achieved in 16 of 17 total metastatic sites. One of 5 patients had new brain mets. Response rate was partial in 3 patients, complete in 1, and stable in another. No patients had brain necrosis. All treatments were delivered within a 30-minute treatment slot. The median total PTV was 20.3 (range, 10.1-169.3) cm3. The median prescribed dose to tumor PTV was 45 (range, 40-45) Gy, median dose to WB (excluding metastasis) was 30 (range, 25-36) Gy, delivered over a median of 15 fractions (range, 10-15). The median PTV coverages were a maximum of 105% and a minimum of 91%. Acute toxicities included 2 patients with Grade 2 (G2) fatigue and 1 patient with G2 alopecia. Common G1 toxicities were rash/dermatitis (7/8) and alopecia (8/8). There were no toxicities >G2. One patient had G2 limb weakness prior to treatment that improved to G1. Two patients had G2 aphasia prior to RT: 1 improved to G1 and another showed complete resolution. Five patients underwent posttreatment MRI at a median time of 112 (range, 45-194) days after the start of treatment. Local brain control was achieved in 16 of 17 total metastatic sites. One of 5 patients had new brain mets. Response rate was partial in 3 patients, complete in 1, and stable in another. No patients had brain necrosis. ConclusionsLow-dose “prophylactic” WBRT can be safely delivered with SIB to brain metastases with minimal toxicity and local control that is comparable to sequential WBRT and stereotactic radiosurgery (SRS). This technique is convenient, non-invasive, and may combine the benefits of WBRT and SRS into one procedure. We are currently accruing patients to further assess toxicity and tumor control using this approach. Low-dose “prophylactic” WBRT can be safely delivered with SIB to brain metastases with minimal toxicity and local control that is comparable to sequential WBRT and stereotactic radiosurgery (SRS). This technique is convenient, non-invasive, and may combine the benefits of WBRT and SRS into one procedure. We are currently accruing patients to further assess toxicity and tumor control using this approach." @default.
• W2065367739 created "2016-06-24" @default.
• W2065367739 creator A5029396383 @default.
• W2065367739 creator A5041045444 @default.
• W2065367739 creator A5049980438 @default.
• W2065367739 creator A5061590943 @default.
• W2065367739 creator A5074158463 @default.
• W2065367739 creator A5079431908 @default.
• W2065367739 creator A5079674985 @default.
• W2065367739 creator A5086825819 @default.
• W2065367739 date "2008-09-01" @default.
• W2065367739 modified "2023-10-02" @default.
• W2065367739 title "Whole Brain Radiation Therapy (WBRT) with Simultaneous Integrated Boost (SIB) to Brain Metastasis via Image Guided, Intensity Modulated Radiation Therapy (IG-IMRT): Dosimetric and Early Clinical Experience" @default.
• W2065367739 doi "https://doi.org/10.1016/j.ijrobp.2008.06.624" @default.
• W2065367739 hasPublicationYear "2008" @default.
• W2065367739 type Work @default.
• W2065367739 sameAs 2065367739 @default.
• W2065367739 citedByCount "5" @default.
• W2065367739 countsByYear W20653677392014 @default.
• W2065367739 countsByYear W20653677392022 @default.
• W2065367739 crossrefType "journal-article" @default.
• W2065367739 hasAuthorship W2065367739A5029396383 @default.
• W2065367739 hasAuthorship W2065367739A5041045444 @default.
• W2065367739 hasAuthorship W2065367739A5049980438 @default.
• W2065367739 hasAuthorship W2065367739A5061590943 @default.
• W2065367739 hasAuthorship W2065367739A5074158463 @default.
• W2065367739 hasAuthorship W2065367739A5079431908 @default.
• W2065367739 hasAuthorship W2065367739A5079674985 @default.
• W2065367739 hasAuthorship W2065367739A5086825819 @default.
• W2065367739 hasBestOaLocation W20653677391 @default.
• W2065367739 hasConcept C120665830 @default.
• W2065367739 hasConcept C121332964 @default.
• W2065367739 hasConcept C121608353 @default.
• W2065367739 hasConcept C126322002 @default.
• W2065367739 hasConcept C126838900 @default.
• W2065367739 hasConcept C143998085 @default.
• W2065367739 hasConcept C19527891 @default.
• W2065367739 hasConcept C2778164965 @default.
• W2065367739 hasConcept C2779013556 @default.
• W2065367739 hasConcept C2989005 @default.
• W2065367739 hasConcept C509974204 @default.
• W2065367739 hasConcept C71924100 @default.
• W2065367739 hasConcept C93038891 @default.
• W2065367739 hasConceptScore W2065367739C120665830 @default.
• W2065367739 hasConceptScore W2065367739C121332964 @default.
• W2065367739 hasConceptScore W2065367739C121608353 @default.
• W2065367739 hasConceptScore W2065367739C126322002 @default.
• W2065367739 hasConceptScore W2065367739C126838900 @default.
• W2065367739 hasConceptScore W2065367739C143998085 @default.
• W2065367739 hasConceptScore W2065367739C19527891 @default.
• W2065367739 hasConceptScore W2065367739C2778164965 @default.
• W2065367739 hasConceptScore W2065367739C2779013556 @default.
• W2065367739 hasConceptScore W2065367739C2989005 @default.
• W2065367739 hasConceptScore W2065367739C509974204 @default.
• W2065367739 hasConceptScore W2065367739C71924100 @default.
• W2065367739 hasConceptScore W2065367739C93038891 @default.
• W2065367739 hasIssue "1" @default.
• W2065367739 hasLocation W20653677391 @default.
• W2065367739 hasOpenAccess W2065367739 @default.
• W2065367739 hasPrimaryLocation W20653677391 @default.
• W2065367739 hasRelatedWork W2049214470 @default.
• W2065367739 hasRelatedWork W2097469776 @default.
• W2065367739 hasRelatedWork W2357126231 @default.
• W2065367739 hasRelatedWork W2364676419 @default.
• W2065367739 hasRelatedWork W2369094418 @default.
• W2065367739 hasRelatedWork W2384708512 @default.
• W2065367739 hasRelatedWork W2860771507 @default.
• W2065367739 hasRelatedWork W2914514705 @default.
• W2065367739 hasRelatedWork W3210704102 @default.
• W2065367739 hasRelatedWork W4387160257 @default.
• W2065367739 hasVolume "72" @default.
• W2065367739 isParatext "false" @default.
• W2065367739 isRetracted "false" @default.
• W2065367739 magId "2065367739" @default.
• W2065367739 workType "article" @default.